65274-89-7

Basic information

• Product Name: 1-(2-chloroethyl)-4-(4-fluorophenyl)-piperazine
• Synonyms: 1-(2-chloroethyl)-4-(4-fluorophenyl)-piperazine
• CAS NO: 65274-89-7
• Molecular Weight: 242.724
• Mol File: 65274-89-7.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1-(2-chloroethyl)-4-(4-fluorophenyl)-piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-chloroethyl)-4-(4-fluorophenyl)-piperazine(65274-89-7)
• EPA Substance Registry System: 1-(2-chloroethyl)-4-(4-fluorophenyl)-piperazine(65274-89-7)

Safety Data

• Hazardous Substances Data: 65274-89-7(Hazardous Substances Data)

Upstream product

• 2252-63-3 1-(4-Fluorophenyl)piperazine 
• 90096-38-1 2-<4-(4-fluorophenyl)piperazin-1-yl>ethanol 
• 16141-90-5 p-Fluorophenylpiperazine hydrochloride 
• 107-04-0 1-Bromo-2-chloroethane 
• 330601-48-4 2-chloro-1-(4-(4-fluorophenyl)piperazin-1-yl)ethanone 

Downstream Products

• 191591-85-2 5-[2-[4-(4-fluorophenyl)piperazin-1-yl]ethyl]-1-methyl-1,4,5,6,7,8-hexahydropyrrolo[3,2-c]azepine-4,8-dione 
• 1092766-59-0 2-{2-[2-(3-methoxyphenyl)ethyl]phenoxy}ethyl-4-(4'-fluorophenyl)piperazine 
• 51299-26-4 1-(2-fluorophenyl)-4-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)piperazine 
• 81513-98-6 3-{2-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-ethyl}-3H-benzooxazol-2-one 

Relevant articles and documents

Novel aryl piperazines for alleviation of ‘andropause’ associated prostatic disorders and depression

A series of seventeen piperazine derivatives have been synthesized and biologically evaluated for the management of andropause-associated prostatic disorders and depression. Five compounds 16, 19, 20, 21 and 22 significantly inhibited proliferation of and

Versatile synthesis of disubstituted triazole library for dopamine and serotonin receptor ligands

-

Synthesis of new 1,2,3-benzotriazin-4-one-arylpiperazine derivatives as 5-HT(1A) serotonin receptor ligands

A series of novel 1,2,3-benzotriazin-4-one derivatives was prepared and evaluated as ligands for 5-HT receptors. Radioligand binding assays proved that the majority of the novel compounds behaved as good to excellent ligands at the 5-HT(1A) receptor, some of which were selective with respect 5-HT(2A) and 5-HT(2C) receptors. Six analogues (1a, 2a, 2b, 2c, 2e and 2i) were selected and further evaluated for their binding affinities on D1, D2 dopaminergic and α1-, α2-adrenergic receptors. A o-OCH3 derivative (2e) bound at 5-HT(1A) sites with subnanomolar affinity (IC50=0.059 nM) and shows high selectivity over all considered receptors and may offer a new lead for the development of therapeutically efficacious agents. Copyright (C) 2000 Elsevier Science Ltd.